Trial Profile
A Randomized, Double-blind, Multi-center, Placebo Parallel controlled Phase II Clinical Study Based on Standard Therapy to Evaluate The Effect and Safety of Recombinant Human Neuregulin-1 for Injection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 May 2013
Price :
$35
*
At a glance
- Drugs Recombinant human neuregulin 1-beta (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- 23 May 2013 Pooled phase II results published in a Zensun Sci & Tech media release.
- 03 Oct 2009 New trial record